<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04799730</url>
  </required_header>
  <id_info>
    <org_study_id>Soh-Med-21-03-01</org_study_id>
    <nct_id>NCT04799730</nct_id>
  </id_info>
  <brief_title>Expression of CXCR4 in Patients With Systemic Lupus Erythematosus</brief_title>
  <official_title>Study of CD184 in Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sohag University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sohag University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to estimate the possible role of CD184 in the pathogenesis of&#xD;
      SLE; comparing its level among SLE cases to healthy controls.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detection of CXCR4 (CD184) expression on CD19+ B cells by flow cytometry in patients of SLE,&#xD;
      comparing its level in the development of lupus activity and pathogenic process of SLE&#xD;
      internal organ involvement/ mucocutaneus and/or musculoskeletal involvement. Identify this&#xD;
      correlation will be useful for clarifying other accessory factors to improve the diagnosis,&#xD;
      better treatment strategy, follow up as well as prognosis for these patients&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>changes in the expression of CD184(CXCR4) expression in circulating B cells</measure>
    <time_frame>6 months</time_frame>
    <description>Flow cytometry analysis of chemokine receptor (CXCR4):Human peripheral-blood mononuclear cells (PBMCs) labeling with CXCR4 antibody will be performed in the same day after taking blood samples and subsequent measurement of the CXCR4 mean fluorescence intensity (MFI) by flow cytometry. MFI of the anti-chemokine receptor (CXCR4) staining will be calculated according to statistical thresholds set in reference to staining with negative control antibodies. The patient's CXCR4 on CD19+ B cells expression or mean MFI will be further compared to the MFI of the simultaneously performed age-matched controls samples and other subgroups of SLE patients.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>SLE cases in remission</arm_group_label>
    <description>according to SLE Disease Activity Index (SLEDAI) inactive disease will be considered as SLEDAI &lt;5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SLE cases in activity</arm_group_label>
    <description>according to SLE Disease Activity Index (SLEDAI) Active disease will be defined as SLEDAI â‰¥ 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Healthy age and sex matched subjects.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      patient's peripheral-blood mononuclear cells (PBMCs) will be isolated from heparinized venous&#xD;
      blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Study population will be classified into two group:&#xD;
&#xD;
          1. SLE patients group: Confirmed SLE patients diagnosed and fulfilled the SLE&#xD;
             classification criteria according to the 2019 ACR/EULAR classification criteria for&#xD;
             SLE (Aringer et al., 2019).&#xD;
&#xD;
          2. Control group: Healthy age and sex matched subjects.&#xD;
&#xD;
        Then SLE group I patients will be subdivided according to the disease activity to three&#xD;
        subgroups:&#xD;
&#xD;
        I. Group A: SLE cases in remission II. Group B: SLE cases in activity, but no internal&#xD;
        organ involvement (i.e. only mucocutaneus and/or musculoskeletal involvement).&#xD;
&#xD;
        III. Group C: SLE cases in activity, and with internal organ involvement (renal,&#xD;
        neuropsychiatric, hematological or cardiopulmonary).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed SLE patients diagnosed and fulfilled the SLE classification criteria&#xD;
             according to the 2019 ACR/EULAR classification criteria for SLE (Aringer et al., 2019)&#xD;
&#xD;
          -  Willing and agreed to be included in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Childhood SLE.&#xD;
&#xD;
          -  SLE-patients will refuse to consent to this study.&#xD;
&#xD;
          -  Other autoimmune diseases.&#xD;
&#xD;
          -  Known or suspected malignancies, especially B cell lymphoma.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Asmaa A Ibrahim, Master</last_name>
    <phone>01032138809</phone>
    <email>smaibrahim2019@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shereen Philip Aziz, Professor</last_name>
    <phone>01033386104</phone>
  </overall_contact_backup>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 14, 2021</study_first_submitted>
  <study_first_submitted_qc>March 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2021</study_first_posted>
  <last_update_submitted>March 14, 2021</last_update_submitted>
  <last_update_submitted_qc>March 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sohag University</investigator_affiliation>
    <investigator_full_name>Asmaa Abdelfattah Ibrahim</investigator_full_name>
    <investigator_title>the Master Degree in Clinical and Chemical Pathology</investigator_title>
  </responsible_party>
  <keyword>CXCR4,CD184,Flow cytometry ,Systemic lupus erythematosus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

